Glow-in-the-Dark dye could help surgeons see hidden cancer cells

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female 18 years of age or older * ECOG performance status 0-2 * Histological confirmation of squamous cell carcinoma * Locating the primary tumour in the oral cavity or oropharynx * Disease operable for complete resection * Serum or urinary pregnancy test (as per centre practices) negative within 14 days prior to systemic indocyanin green injection (pre-operative visit), for women of childbearing age * Patient information and signed free and informed consent * Patient affiliated with a social security scheme or beneficiary of a similar scheme. * The patient must understand, sign and date the consent form prior to any protocol-specific procedures. The patient must be able and willing to comply with the study visits and procedures described in the protocol Exclusion Criteria: * Severe medical co-morbidities or contraindications to surgery * Primary tumour not operable * History of head and neck cancer in the past 5 years * History of radiation for head and neck cancer * Metastatic cancer * Tumours with necrosis ranges in pre-operative imaging * History of invasive cancer unless there has been no recurrence for more than 5 years with an exception for non-melanoma skin cancers. * Pregnant or nursing woman * Allergy or hypersensitivity to the product being administered (its active substance or other ingredients), iodized products or crustaceans. * Hyperthyroidism, thyroid adenoma, unifocal, multifocal or multinodular goiter of autoimmune origin. * Documented coronary artery disease * Advanced renal failure (creatinine \> 1.5mg/dL). * Within 2 weeks prior to inclusion, concomitant medication that reduces or increases extinction of GI (i.e. anticonvulsants, haloperidol and Heparin). * Patient under guardianship or curatorship or deprived of liberty by judicial or administrative decision or patient unable to give consent. * Patients unable to undergo medical follow-up of the trial